Valeant's outgoing CEO made an insane amount of money last year
Screenshot/ABC News
It was the year the international giant was brought to its knees.
In October accusations of malfeasance from a short seller combined with government scrutiny over Valeant's drug pricing practices to drag its stock down almost 70%.
Pearson stepped down from the company earlier this month, after it was forced to change its business model, shut down a previously undisclosed internal pharmacy called Philidor, and filed its annual report over a month late, risking defaulting on its $30 billion debt load.
On Wednesday, Pearson, the company's former CFO and billionaire hedge fund investor and board member Bill Ackman testified before Congress, answering for hiking the prices of a number of critical drugs to exhorbitant levels.
Since then the company has also announced that longstanding board members will step down.
New CEO Joe Papa starts on Monday.
NOW WATCH: How ISIS makes over $1 billion a year
- Thailand is now welcoming Indians with open arms, but are its drought-hit islands really prepared for a tourism influx?
- Thoughtful gift ideas to make Mother's Day extra special
- Muslims up, Hindus down: What’s the larger picture behind India’s religious population trends?
- Scooch over magic mushrooms, toad venom could be the next big psychedelic for depression and anxiety!
- TBO Tek IPO allotment – How to check allotment, GMP, listing date and more
- Nothing Phone (2a) blue edition launched
- JNK India IPO allotment date
- JioCinema New Plans
- Realme Narzo 70 Launched
- Apple Let Loose event
- Elon Musk Apology
- RIL cash flows
- Charlie Munger
- Feedbank IPO allotment
- Tata IPO allotment
- Most generous retirement plans
- Broadcom lays off
- Cibil Score vs Cibil Report
- Birla and Bajaj in top Richest
- Nestle Sept 2023 report
- India Equity Market